The Medication Can Start the Journey. Habits Finish It.

Medications like Ozempic, Wegovy, and Zepbound have changed how people talk about weight. Studies show that many people lose significant weight while taking them. Other studies show something that gets less attention: when people stop the drug, much of the weight tends to come back within a year (Aronne et al., 2024; Wilding et al., 2022). So, the better question is not just “Does it work?” It is “What habits am I building while it works?”
What is a GLP-1?
GLP-1 is a hormone your gut makes after you eat. It helps your body handle blood sugar, slows how fast your stomach empties, and helps you feel full. GLP-1 medications copy that hormone. People taking them tend to feel less hungry, eat less, and lose weight (Nauck et al., 2021).
These drugs were not created for weight loss. They were created to treat type 2 diabetes, and the first one was approved for that purpose in 2005 (Nauck et al., 2021). Weight loss showed up as a side benefit. Newer versions turned out to be stronger for both blood sugar and weight.
You probably know them by their brand names. The same drug is often sold under one name for diabetes and another for weight loss (Twenter, 2025):
Drug | Brand names | Main approved use |
Semaglutide | Ozempic, Rybelsus | Type 2 diabetes |
Semaglutide | Wegovy | Weight loss |
Tirzepatide | Mounjaro | Type 2 diabetes |
Tirzepatide | Zepbound | Weight loss |
Liraglutide | Victoza | Type 2 diabetes |
Liraglutide | Saxenda | Weight loss |
Dulaglutide | Trulicity | Type 2 diabetes |
Exenatide | Byetta, Bydureon | Type 2 diabetes |
Some of these are also approved for other uses, such as lowering the risk of heart problems in certain patients, lowering the risk of worsening kidney disease in some people with diabetes (Ozempic), and treating sleep apnea (Zepbound) or a type of fatty liver disease (Wegovy) (Twenter, 2025). Mounjaro and Zepbound copy GLP-1 plus a second gut hormone, but most people group them with the GLP-1s.
Who are these medications meant for?
At first, they were for adults with type 2 diabetes.
For weight loss, the original rule is the one most people have heard. It uses body mass index, or BMI, which compares your weight to your height. When Wegovy was first approved, it was for adults with a BMI of 30 or higher, or a BMI of 27 or higher along with a weight-related health problem such as high blood pressure, type 2 diabetes, or high cholesterol (U.S. Food and Drug Administration [FDA], 2021). The big studies enrolled people using a similar rule, though they excluded people with diabetes (Aronne et al., 2024; Wilding et al., 2022).
The list has grown since then. Wegovy is now also approved to lower the risk of heart attack, stroke, and heart-related death in adults who already have heart or blood vessel disease, to treat a type of fatty liver disease (MASH) in some adults, and for weight loss in patients as young as 12 who have obesity (FDA, 2026). Wegovy now also comes as a daily pill for adults (FDA, 2026). Whether one of these medications is right for you is a decision for you and your doctor.
How does a GLP-1 compare with the keto diet?
They are very different tools. Keto is a way of eating that cuts carbohydrates to about 50 grams a day or less. A GLP-1 is a prescription medication that lowers your appetite.
GLP-1 medication | Keto diet | |
What it is | A prescription drug, usually a weekly shot | An eating plan very low in carbs |
Who is in charge | Your doctor | You, ideally with your doctor’s knowledge |
Weight loss in studies | About 15% of body weight in roughly 16 months on semaglutide, compared with about 2% on a dummy shot, with diet and exercise support (Wilding et al., 2022) | About 2 pounds more than a low-fat diet after a year or longer (Bueno et al., 2013) |
Other findings | Stomach upset is the most common side effect (FDA, 2026) | The lower blood pressure number, blood fats, and “good” cholesterol improved slightly, but “bad” cholesterol went up (Bueno et al., 2013) |
The hard part | Staying on it, and what happens when you stop | Sticking with it for years |
A caution: no study here tested the two side by side, so this is not a direct contest. The numbers also measure different things: the drug figure is total weight lost, while the keto figure is the extra weight lost compared with another diet. The keto researchers themselves said the long-term differences they found were small (Bueno et al., 2013).
What the two have in common matters more. Neither a prescription nor a diet plan builds lasting habits.
What do doctors and the FDA say about using one?
The medication is not meant to do the job alone. Wegovy is approved for use along with eating fewer calories and being more active (FDA, 2026). The official instructions also include cautions worth discussing with your doctor:
The strongest warning is about a type of thyroid tumor seen in animal studies. People who have had a thyroid cancer called medullary thyroid cancer, or who have it or a related inherited condition in their family, should not take the drug.
Other warnings include severe stomach and gut side effects, allergic reactions, an inflamed pancreas, gallbladder problems, kidney problems caused by dehydration, and low blood sugar when combined with some diabetes medicines, among others.
The most common side effects are nausea, diarrhea, vomiting, and constipation.
The drug should be stopped if you become pregnant, and at least two months before a planned pregnancy.
In 2025, four medical groups focused on obesity, nutrition, and healthy living published advice for doctors. They named the everyday problems: stomach side effects, not getting enough nutrients when you eat less, losing muscle and bone along with fat, and many people quitting the drug. Their advice is that everyone prescribed a GLP-1 should also be offered a program that helps with food, exercise, tracking progress, and problem-solving. They also recommend strength training at least three times a week and at least 150 minutes of moderate exercise each week (Mozaffarian et al., 2025).
What happens when you stop?
Two studies looked at this: a follow-up of part of one large trial, and a trial designed to test stopping.
In the first, researchers followed about 230 people for a year after they stopped taking semaglutide and ended the study’s diet and exercise program, along with a comparison group that had taken a dummy shot. On the drug, this group had lost about 17% of their body weight on average. A year later, they had gained back about two-thirds of what they lost. Most improvements in their other health measures also faded (Wilding et al., 2022).
In the second, adults lost about 21% of their weight in roughly eight months on tirzepatide. Then half of them were switched, without knowing it, to a shot with no medicine in it. Over the next year, that group’s weight went back up by 14%. The people who stayed on the real drug lost another 5.5%, and even the dummy-shot group still ended about 10% below their starting weight (Aronne et al., 2024).
Both research teams reached the same conclusion. Excess weight behaves like a long-term health condition, and the benefits mostly last only as long as the treatment does. Yet many people do stop. In the real-world prescription data the medical groups reviewed, between half and two-thirds of patients had quit within a year (Mozaffarian et al., 2025). Stopping, restarting, or changing your dose is a decision to make with your doctor.
What about staying on a GLP-1 for years?
Medical groups increasingly support staying on treatment long term. They now describe excess weight as a long-term health condition, like high blood pressure, that often calls for long-term treatment (American Diabetes Association Professional Practice Committee for Obesity [ADA], 2026; Aronne et al., 2024).
The benefits of staying on
The weight tends to stay off. In a study of more than 17,000 adults aged 45 and older who had heart or blood vessel disease, most of them men, people taking semaglutide were about 10% lighter after four years. People taking a dummy shot were 1.5% lighter (Ryan et al., 2024).
Heart protection for some people. That same study followed adults aged 45 and older who already had cardiovascular (heart or blood vessel) disease and did not have diabetes. Over a little more than three years, 6.5% of those on semaglutide had a heart attack or a stroke, or died of heart-related causes, compared with 8.0% of those on the dummy shot. That is a 20% lower risk (Lincoff et al., 2023). The study was paid for by the drug’s maker, and it did not test people without cardiovascular disease.
No regain cycle. Staying on avoids weight regain and loss of health gains that often follow stopping (ADA, 2026).
The disadvantages
Side effects can wear people down. In the heart study, 16.6% of people on semaglutide quit because of side effects, compared with 8.2% on the dummy shot (Lincoff et al., 2023).
Your body needs looking after. Eating less for years can mean too little protein and too few nutrients, and weight loss can take muscle and bone along with fat (Mozaffarian et al., 2025).
Cost. These drugs are expensive. In 2025, U.S. list prices ran about $12,000 to $16,000 a year, or about $7,000 to $8,000 with manufacturer discounts, and insurance coverage varies. The cost continues for as long as you take them (Mozaffarian et al., 2025).
Unanswered questions. The World Health Organization says information on long-term safety is still limited, and that it is not yet clear how best to handle “maintenance” doses or stopping (World Health Organization [WHO], 2025).
What medical groups recommend
The American Diabetes Association’s obesity guideline, published in January 2026, advises continuing the medication after you reach your goals, because stopping often brings the weight and related health problems back. It notes the long-term dose may be lower than the maximum. It also calls for regular check-ups: at least monthly for the first three months, every three months for the rest of the first year, and every six months after that. Along the way, your care team should watch your nutrition, and you should get enough protein and do muscle-strengthening exercise (ADA, 2026).
In December 2025, the World Health Organization issued its first guideline on these drugs. It says they may be used as long-term treatment for adults with obesity (but not during pregnancy), and that people taking them may also be given structured support with eating and physical activity. The WHO calls both recommendations “conditional.” For the medication, this is because there is still limited information on long-term results and safety, maintenance and stopping, and cost and access. For the support programs, it is because the evidence is low certainty (WHO, 2025).
How long you stay on a GLP-1, and at what dose, is a decision for you and your doctor.
How coaching fits when the plan is long-term
If you are staying on the medication, coaching is not about preparing for the end. It is about making the long run work. The medication manages appetite. It does not get you to strength training, plan your meals around enough protein, or keep you going when the scale stops moving, which in the four-year study happened after about 15 months (Ryan et al., 2024). A wellness coach can help you:
Build and keep the strength and movement habit the guidelines call for.
Turn your doctor’s or dietitian’s eating guidance into routines you can live with.
Stay on schedule with check-ups and arrive with your questions ready.
Set goals that reflect how you live now that the weight goal is behind you.
The same honesty applies here. The WHO rates the evidence that structured lifestyle support improves results on a GLP-1 as low certainty (WHO, 2025). And a coach does not advise on your dose or side effects. Those conversations belong with your doctor.
Where does wellness coaching fit?
A GLP-1 can turn down your appetite. It cannot decide how you eat, move, sleep, and handle stress once your appetite comes back. That takes habits, and habits take practice over time.
The same medical groups list health coaches as part of the team that supports people taking a GLP-1. They also point to what people who keep weight off tend to do: stay active, keep track of their progress, plan ahead, solve problems as they come up, and lean on support from others (Mozaffarian et al., 2025). Those are the things a wellness coach helps you practice:
Getting clear on what you want better health to make possible, beyond a number on the scale.
Turning your doctor’s advice into small routines that fit your week.
Building an exercise habit you will keep.
Keeping you on track and helping you work it out when a routine falls apart.
Getting ready, together with your doctor, for the day your treatment changes.
One honest caution. As of 2025, the medical groups pointed out that programs like these had not been tested in controlled trials to prevent weight from coming back after someone stops a GLP-1 (Mozaffarian et al., 2025). Coaching does not guarantee the weight stays off, and it does not replace your doctor. What it gives you is a way to use your months on the medication to practice the habits you want to keep.
Since then, early evidence has started to arrive. In a small study published in October 2026, 39 adults who had lost more than 10% of their weight on a GLP-1 and then stopped were randomly assigned to three groups. One group got usual care. One used a behavior-change app. One received meals tailored to their health needs. After four months, the usual-care group had gained an estimated 11% of their body weight. The other two groups had each gained less than 4% (Hollis-Hansen et al., 2026). This was a small, short test, and it did not study one-on-one coaching, so it is a promising sign rather than proof. Weight was also a secondary measure, and the groups did not differ on the study’s main goals of sticking with the program and being satisfied with it. Still, it adds to early signs that structured support at the moment of stopping may help.
A coach does not prescribe, diagnose, change your medication, or write meal plans. Your doctor manages the treatment. A coach helps you build the life around it.
Book an appointment today at https://www.myjourneytowellness.co/book-online to see what we can do for you or your team.
Disclaimer
This article is for general education only. It is not medical advice, diagnosis, or treatment, and it does not create a coach-client or professional relationship. My Journey To Wellness LLC provides wellness coaching and education; we do not prescribe, recommend, or advise on starting, stopping, or changing any medication. Always talk with your doctor or other qualified health care provider before starting, stopping, or changing a medication, diet, or exercise program, and about any questions you have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you read here. Individual results vary, and no outcome is guaranteed. If you think you may have a medical emergency, call 911.
References
American Diabetes Association Professional Practice Committee for Obesity. (2026). Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. Diabetes, Obesity, and Cardiometabolic CARE, 1(1), 5–36. https://doi.org/10.2337/doci25-0008
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., & Murphy, M. A. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
Bueno, N. B., de Melo, I. S. V., de Oliveira, S. L., & da Rocha Ataide, T. (2013). Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: A meta-analysis of randomised controlled trials. British Journal of Nutrition, 110(7), 1178–1187. https://doi.org/10.1017/S0007114513000548
Hollis-Hansen, K., Vonderschmidt, A., Haskins, C., Kane, R. M., Almandoz, J. P., & Lingvay, I. (2026). Preventing weight regain after glucagon-like peptide-1 therapy discontinuation: A pilot randomized controlled trial. Obesity Science & Practice, 12(5), Article e70194. https://doi.org/10.1002/osp4.70194
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 122(1), 344–367. https://doi.org/10.1016/j.ajcnut.2025.04.023
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, Article 101102. https://doi.org/10.1016/j.molmet.2020.101102
Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhöfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 30(7), 2049–2057. https://doi.org/10.1038/s41591-024-02996-7
Twenter, P. (2025, October 20). GLP-1 drug approvals: A breakdown. Becker’s Hospital Review. https://www.beckershospitalreview.com/glp-1s/glp-1-drug-approvals-a-breakdown/
U.S. Food and Drug Administration. (2021). Wegovy (semaglutide) injection: Prescribing information (Rev. 06/2021). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000Lbl.pdf
U.S. Food and Drug Administration. (2026). Wegovy (semaglutide) injection and tablets: Prescribing information (Rev. 03/2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256Orig1s029,%20218316Orig1s005lbl.pdf
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
World Health Organization. (2025, December 1). WHO issues global guideline on the use of GLP-1 medicines in treating obesity [News release]. https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
Comments